Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Amphastar Pharmaceuticals, Inc. (AMPH : NSDQ)
 
 • Company Description   
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.

Number of Employees: 2,028

 
 • Price / Volume Information   
Yesterday's Closing Price: $23.20 Daily Weekly Monthly
20 Day Moving Average: 447,863 shares
Shares Outstanding: 47.14 (millions)
Market Capitalization: $1,093.63 (millions)
Beta: 0.72
52 Week High: $53.96
52 Week Low: $22.64
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -10.73% -14.70%
12 Week -3.97% -17.98%
Year To Date -37.52% -41.47%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11570 SIXTH STREET
-
RANCHO CUCAMONGA,CA 91730
USA
ph: 909-980-9484
fax: 909-980-8296
jasons@amphastar.com http://www.amphastar.com
 
 • General Corporate Information   
Officers
Jack Yongfeng Zhang - Chief Executive Officer and President
Mary Z. Luo - Chairman and Chief Operating Officer
William J. Peters - Chief Financial Officer
Jacob Liawatidewi - Executive Vice President
Gayle M. Deflin - Director

Peer Information
Amphastar Pharmaceuticals, Inc. (BGMR)
Amphastar Pharmaceuticals, Inc. (BBIO)
Amphastar Pharmaceuticals, Inc. (IPAH)
Amphastar Pharmaceuticals, Inc. (BRL)
Amphastar Pharmaceuticals, Inc. (BHC)
Amphastar Pharmaceuticals, Inc. (AKRXQ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-GENERIC DRG
Sector: Medical
CUSIP: 03209R103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
Share - Related Items
Shares Outstanding: 47.14
Most Recent Split Date: (:1)
Beta: 0.72
Market Capitalization: $1,093.63 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.76 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $2.82 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 1.36% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 8.22
Trailing 12 Months: 7.34
PEG Ratio: 6.04
Price Ratios
Price/Book: 1.47
Price/Cash Flow: 4.64
Price / Sales: 1.50
EPS Growth
vs. Year Ago Period: -34.41%
vs. Previous Quarter: -26.51%
Sales Growth
vs. Year Ago Period: -0.76%
vs. Previous Quarter: -8.58%
ROE
06/30/25 - -
03/31/25 - 22.20
12/31/24 - 25.52
ROA
06/30/25 - -
03/31/25 - 10.40
12/31/24 - 11.73
Current Ratio
06/30/25 - -
03/31/25 - 2.95
12/31/24 - 3.07
Quick Ratio
06/30/25 - -
03/31/25 - 2.02
12/31/24 - 2.19
Operating Margin
06/30/25 - -
03/31/25 - 22.22
12/31/24 - 24.80
Net Margin
06/30/25 - -
03/31/25 - 19.38
12/31/24 - 21.79
Pre-Tax Margin
06/30/25 - -
03/31/25 - 23.64
12/31/24 - 25.92
Book Value
06/30/25 - -
03/31/25 - 15.82
12/31/24 - 15.23
Inventory Turnover
06/30/25 - -
03/31/25 - 2.44
12/31/24 - 2.74
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.80
12/31/24 - 0.82
Debt-to-Capital
06/30/25 - -
03/31/25 - 44.56
12/31/24 - 45.10
 

Powered by Zacks Investment Research ©